Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ind-Swift LaboratoriesNSE:INDSWFTLAB +2.02%48 Debt-to-EBITDA is 0.25 as of Mar. 2026, which is 94% below its 10-year median of 4.44. GuruFocus rates NSE:INDSWFTLAB with a GF Score™ of 48/100 and a GF Value™ of ₹44.67 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 692 Drug Manufacturers companies, Ind-Swift Laboratories ranks better than 77.75% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Ind-Swift Laboratories's Debt-to-EBITDA or its related term are showing as below:
NSE:INDSWFTLAB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.14 Med: 4.44 Max: 11.54
Current: 0.31
During the past 13 years, the highest Debt-to-EBITDA Ratio of Ind-Swift Laboratories was 11.54. The lowest was 0.14. And the median was 4.44.
NSE:INDSWFTLAB's Debt-to-EBITDA is ranked better than 77.75% of 692
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs NSE:INDSWFTLAB: 0.31
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Ind-Swift Laboratories Debt-to-EBITDA Related Terms
Ind-Swift Laboratories Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Ind-Swift Laboratories's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ind-Swift Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ind-Swift Laboratories Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ind-Swift Laboratories's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ind-Swift Laboratories's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Ind-Swift Laboratories (NSE:INDSWFTLAB) has a Debt-to-EBITDA of 0.25 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ind-Swift Laboratories. This is 94% below median its historical median of 4.44. Over the past decade, Ind-Swift Laboratories' Debt-to-EBITDA has ranged from 0.14 to 11.54. According to the industry distribution chart, Ind-Swift Laboratories ranks #154 out of 692 companies in the Drug Manufacturers industry, placing it in the top 22.3%.
Is Ind-Swift Laboratories' Debt-to-EBITDA too high?
Ind-Swift Laboratories' current Debt-to-EBITDA of 0.25 is 94% below median its 10-year median of 4.44. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 11.54. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Ind-Swift Laboratories' value of 0.25 is 85.1% below this industry median. Based on the distribution chart, Ind-Swift Laboratories ranks #154 out of 692 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ind-Swift Laboratories has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ind-Swift Laboratories' Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ind-Swift Laboratories ranks #154 out of 692 companies for Debt-to-EBITDA. This places Ind-Swift Laboratories in the top 22% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.68. Ind-Swift Laboratories' value of 0.25 is 85.1% below this benchmark. Historically, Ind-Swift Laboratories' own Debt-to-EBITDA has ranged from 0.14 to 11.54 over the past decade. While the company's 10-year median is 4.44 vs. the industry median of 1.68, Ind-Swift Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ind-Swift Laboratories's current Debt-to-EBITDA of 0.25 is 85.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ind-Swift Laboratories. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ind-Swift Laboratories's current Debt-to-EBITDA is 0.25, which is 94% below median its own 10-year median of 4.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ind-Swift Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ind-Swift Laboratories (NSE:INDSWFTLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹44.67, compared to a current price of ₹224.27 — trading 402.1% above its estimated fair value. The current Debt-to-EBITDA is 0.25, which is 94% below median its 10-year median of 4.44 and 85.1% below the Drug Manufacturers industry median of 1.68. Ind-Swift Laboratories' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Ind-Swift Laboratories (NSE:INDSWFTLAB), the current Debt-to-EBITDA is 0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ind-Swift Laboratories (NSE:INDSWFTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Ind-Swift Laboratories stock appears to be overvalued.
The current stock price of ₹224.27 is trading 402.1% above its estimated GF Value™ of ₹44.67.
GuruFocus considers Ind-Swift Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:INDSWFTLAB:
Debt-to-EBITDA: 0.25 (94% below median its 10-year median of 4.44)
GF Value™: ₹44.67 vs. price of ₹224.27 (402.1% above fair value)
Industry Position: 85.1% below the Drug Manufacturers median (#154 of 692)
No single metric tells the full story. See the NSE:INDSWFTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ind-Swift Laboratories Ltd is involved in manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company serves various therapeutic segments, including Cardiovascular health, Antihistamines, Antidiabetics, Antipsychotics, Parkinson's disease, Antineoplastics, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitors. It operates solely in the pharmaceutical products sector. Geographically, the company supplies both domestic and international markets, with the majority of its revenue coming from outside India.
48GF Score
Get the complete analysis for NSE:INDSWFTLAB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDSWFTLAB has been successfully added to your 
